Alert: A Powerful Small Cap Trend is Unfolding in India
Here is the latest financial fact sheet of ZENITH DRUGS LTD.. For more details, see the ZENITH DRUGS LTD. quarterly results and ZENITH DRUGS LTD. share price. For a sector overview, read our pharmaceuticals sector report.
1 Day | % | -4.8 |
No. of shares | m | 17.15 |
1 Week | % | 22.5 |
1 Month | % | 16.1 |
1 Year | % | - |
52 week H/L | Rs | 114.5/52.8 |
No. of Mths Year Ending |
12 Mar-21* |
12 Mar-22* |
12 Mar-23* |
5-Yr Chart Click to enlarge
|
---|
ZENITH DRUGS LTD. EQUITY SHARE DATA | |||||||
---|---|---|---|---|---|---|---|
High | Rs | NA | NA | NA | |||
Low | Rs | NA | NA | NA | |||
Sales per share (Unadj.) | Rs | 1,642.0 | 2,291.4 | 2,863.0 | |||
Earnings per share (Unadj.) | Rs | 76.7 | 78.2 | 128.8 | |||
Diluted earnings per share | Rs | 1.8 | 1.8 | 3.0 | |||
Cash flow per share (Unadj.) | Rs | 107.2 | 111.4 | 161.4 | |||
Dividends per share (Unadj.) | Rs | 0 | 0 | 0 | |||
Adj. dividends per share | Rs | 0.00 | 0.00 | 0.00 | |||
Avg Dividend yield | % | 0 | 0 | 0 | |||
Book value per share (Unadj.) | Rs | 241.0 | 302.3 | 431.1 | |||
Adj. book value per share | Rs | 5.6 | 7.1 | 10.1 | |||
Shares outstanding (eoy) | m | 0.40 | 0.40 | 0.40 | |||
Price / Sales ratio | x | 0 | 0 | 0 | |||
Avg P/E ratio | x | 0 | 0 | 0 | |||
P/CF ratio (eoy) | x | 0 | 0 | 0 | |||
Price / Book Value ratio | x | 0 | 0 | 0 | |||
Dividend payout | % | 0 | 0 | 0 | |||
Avg Mkt Cap | Rs m | 0 | 0 | 0 | |||
Total wages/salary | Rs m | 24 | 28 | 39 |
ZENITH DRUGS LTD. INCOME DATA | |||||||
---|---|---|---|---|---|---|---|
Net Sales | Rs m | 657 | 917 | 1,145 | |||
Other income | Rs m | 1 | 10 | 12 | |||
Total revenues | Rs m | 658 | 927 | 1,157 | |||
Gross profit | Rs m | 72 | 70 | 100 | |||
Depreciation | Rs m | 12 | 13 | 13 | |||
Interest | Rs m | 15 | 22 | 26 | |||
Profit before tax | Rs m | 46 | 44 | 72 | |||
Minority Interest | Rs m | 0 | 0 | 0 | |||
Prior Period Items | Rs m | 0 | 0 | 0 | |||
Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | |||
Tax | Rs m | 15 | 13 | 21 | |||
Profit after tax | Rs m | 31 | 31 | 52 | |||
Gross profit margin | % | 11.0 | 7.6 | 8.7 | |||
Effective tax rate | % | 33.3 | 29.0 | 28.5 | |||
Net profit margin | % | 4.7 | 3.4 | 4.5 |
ZENITH DRUGS LTD. BALANCE SHEET DATA | |||||||
---|---|---|---|---|---|---|---|
Current assets | Rs m | 358 | 535 | 839 | |||
Current liabilities | Rs m | 294 | 466 | 718 | |||
Net working cap to sales | % | 9.9 | 7.6 | 10.6 | |||
Current ratio | x | 1.2 | 1.1 | 1.2 | |||
Inventory Days | Days | 8 | 8 | 7 | |||
Debtors Days | Days | 1,300 | 1,277 | 1,572 | |||
Net fixed assets | Rs m | 107 | 151 | 140 | |||
Share capital | Rs m | 4 | 4 | 4 | |||
"Free" reserves | Rs m | 92 | 117 | 168 | |||
Net worth | Rs m | 96 | 121 | 172 | |||
Long term debt | Rs m | 73 | 96 | 84 | |||
Total assets | Rs m | 465 | 686 | 979 | |||
Interest coverage | x | 4.1 | 3.0 | 3.7 | |||
Debt to equity ratio | x | 0.8 | 0.8 | 0.5 | |||
Sales to assets ratio | x | 1.4 | 1.3 | 1.2 | |||
Return on assets | % | 9.8 | 7.8 | 8.0 | |||
Return on equity | % | 31.8 | 25.9 | 29.9 | |||
Return on capital | % | 36.0 | 30.7 | 38.5 | |||
Exports to sales | % | 0 | 0 | 0 | |||
Imports to sales | % | 0 | 0 | 0 | |||
Exports (fob) | Rs m | 0 | 0 | 0 | |||
Imports (cif) | Rs m | 0 | 0 | 0 | |||
Fx inflow | Rs m | 0 | 0 | 0 | |||
Fx outflow | Rs m | 0 | 0 | 0 | |||
Net fx | Rs m | 0 | 0 | 0 |
ZENITH DRUGS LTD. CASH FLOW | |||||||
---|---|---|---|---|---|---|---|
From Operations | Rs m | -9 | 52 | -44 | |||
From Investments | Rs m | -14 | -52 | 1 | |||
From Financial Activity | Rs m | 29 | 12 | 49 | |||
Net Cashflow | Rs m | -2 | 12 | 6 |
Share Holding
Shareholding as on Mar 2024
|
Company Information
|
CHM: Sandeep Bhardwaj | COMP SEC: Sakshi Bhawsar | YEAR OF INC: 2000 | NSE CODE: 100072 | FV (Rs): 10 | DIV YIELD (%): - |
More Pharmaceuticals Company Fact Sheets: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Compare ZENITH DRUGS LTD. With: DIVIS LABORATORIES DR. REDDYS LAB ZYDUS LIFESCIENCES CIPLA SUN PHARMA
Asian shares edged higher on Wednesday as anxious investors dared to hope AI-diva Nvidia could meet sky-high expectations, while keeping a wary eye on the outlook for US and UK interest rates.